ClinicalTrials.gg
RecruitingNCT07226999Symbiotic-LungUpdated Nov 18, 2026

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer

A Phase 2/3 interventional study of PF-08634404 and Tarlatamab in Small Cell Lung Cancer (SCLC), sponsored by Pfizer. Recruiting at 85 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

How we know · 12 judgments · 2 readings being read again

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 18, 2026Eligibility revisedPrimary outcomes revised+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Small Cell Lung Carcinoma by Pfizer — 4 open to participants now, 5 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Pfizer.

Planned enrollment
2nd of 12
550 · median 227
Started
2025
the only one that year
Phase 2/3
Only one
of the 12
Registered
11th of 12
by date

Among the 12 studies in Small Cell Lung Carcinoma by Pfizer, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 11th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

4 of the 12 studies in Small Cell Lung Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Small Cell Lung Carcinoma by Pfizer, or all of them as a file.
02

Study summary

This study is being done to learn more about an investigational medicine called PF-08634404 when used alone or in combination with other anti-cancer medicines in adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread beyond the lung.

PF-08634404 is designed to target two pathways involved in cancer growth and survival. The study will also evaluate combinations with chemotherapy and tarlatamab, an approved immunotherapy that helps the body's immune system recognize and attack small cell lung cancer cells.

To join the study, participants must meet the following conditions:

  • 18 years of age or older.
  • Have extensive-stage small cell lung cancer confirmed by laboratory testing.
  • Have measurable disease on imaging scans.
  • Be in generally good physical condition and have adequate organ function.
  • For most study groups, have not received prior systemic treatment for extensive-stage small cell lung cancer, although participants who received a single cycle of chemotherapy for life-threatening disease-related symptoms are eligible.

The study has two parts:

Phase 2 Researchers will evaluate the safety, tolerability, and preliminary anti-cancer activity of PF-08634404.

Participants may receive:

  • PF-08634404 plus chemotherapy,
  • PF-08634404 plus tarlatamab, or
  • PF-08634404 plus tarlatamab and chemotherapy.

The results will help determine the recommended dose and treatment regimen for future study.

Phase 3 Researchers will compare PF-08634404 plus chemotherapy with an approved treatment regimen consisting of atezolizumab plus chemotherapy.

The goal is to determine whether PF-08634404 can improve outcomes such as overall survival.

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)

Keywords

  • small cell lung cancer
  • extensive stage small cell lung cancer
  • first-line
  • tarlatamab
  • Symbiotic
  • PF-08634404
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • For Phase 2 (except the Part B doublet cohort) and Phase 3: no prior systemic therapy for ES-SCLC. Participants who received 1 cycle of chemotherapy (without immunotherapy) for management of life-threatening ES-SCLC are eligible if all other criteria are met.
  • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
  • Have at least one as the targeted lesion based on V1.1.
  • performance status of 0 or 1.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) lesions, including brainstem, meningeal, or spinal cord /compression. Participants with adequately treated and stable , or certain untreated asymptomatic brain metastases, may be eligible.
  • risk of hemorrhage or fistula, including radiographic evidence of major blood vessel invasion/infiltration or tumor invasion of critical organs.
  • History of another within 2 years, except for certain low-risk cancers.
  • Active diseases requiring systemic treatment within the past 2 years
  • Evidence of non-infectious/drug-induced interstitial lung disease (ILD) or pneumonitis, or certain severe pulmonary conditions.
  • Uncontrolled significant comorbidities within 6 months before study treatment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Phase 2 Part A - Chemo Combo Arm

    Participants will receive PF-08634404 in combination with chemotherapy

    Drug: PF-08634404 · Drug: Chemotherapy

  • Experimental
    Phase 2 Part B - Doublet Arm

    Participants will receive PF-08634404 in combination with tarlatamab

    Drug: PF-08634404 · Drug: Tarlatamab

  • Experimental
    Phase 2 Part B - Triplet Arm

    Participants will receive PF-08634404 in combination with tarlatamab and chemotherapy.

    Drug: PF-08634404 · Drug: Tarlatamab · Drug: Chemotherapy

  • Experimental
    Phase 3 Experimental Arm

    Participants will receive PF-08634404 in combination with chemotherapy

    Drug: PF-08634404 · Drug: Chemotherapy

  • Active comparator
    Phase 3 Control Arm

    Participants will receive atezolizumab in combination with chemotherapy

    Drug: Chemotherapy · Drug: Atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2: Number of participants with treatment-emergent adverse events

    Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

    Time frame: Up to 90 days after the last dose of treatment

  2. Phase 3: Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

Secondary outcomes

  1. Confirmed ORR using RECIST v1.1 as assessed by investigator

    ORR is defined as the proportion of participants in the analysis population having a BOR of confirmed CR or confirmed PR according to RECIST v1.1 as assessed by investigator

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  2. Duration of Response (DOR) as assessed by Investigator based on RECIST v1.1

    DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of PD or death due to any cause.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  3. Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1

    PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  4. Number of participants with Laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

    Time frame: Up to 90 days after the last dose of treatment

  5. Phase 2: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)

    DLT (any of the prespecified AEs that are attributable to study treatment(s), excluding toxicities clearly due to underlying disease or extraneous causes) rate estimated based on data from DLT-evaluable participants during the DLT evaluation period.

    Time frame: Up to 90 days after the last dose of treatment

  6. Phase 2: Overall Survival

    Overall survival defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  7. Phase 3: PFS using RECIST v1.1 as assessed by blinded independent central review (BICR)

    Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  8. Phase 3: Confirmed ORR using RECIST v1.1 as assessed by BICR

    ORR is defined as the proportion of participants in the analysis population having a BOR of confirmed CR or confirmed PR according to RECIST v1.1 as assessed by BICR.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  9. Phase 3: DOR using RECIST v1.1 as assessed by BICR

    The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of the first documentation of PD as determined by BICR assessment per RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  10. Incidence of antidrug antibody against PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  11. Pharmacokinetics: Serum concentrations of PF-08634404

    Time frame: Up to 37 days after the last dose of treatment

  12. Phase 3: Mean scores and Change from baseline in the global health status/quality of life (QoL), function, and symptom scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a questionnaire for quantitative measure of health-related quality of life pertinent to participants with a broad range of cancers who are participating in international clinical trials.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  13. Phase 3: Mean scores and Change from Baseline on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 (EORTC QLQ-LC13)

    EORTC QLQ-LC13 is a lung cancer specific module that serves as an additional 13 item questionnaire to the general EORTC cancer questionnaire, the EORTC QLQ-C30.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  14. Phase 3: Time to definitive deterioration (TTdD) in the global health status/QoL, function, and symptom scores on the EORTC QLQ-C30

    TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

  15. Phase 3: TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13

    TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.

    Time frame: Up to approximately 2 years after completion of study treatment of last study participant

07

Study locations

83 of 85 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jun 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Jun 14, 2030
CompletionEst.
Mar 11, 2034
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed. 17 sites changed recruiting status (17 now recruiting)
Show 17 sites
  • University Hospitals Cleveland Medical Center · Cleveland, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Allen, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Bedford, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Denison, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Denton, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Flower Mound, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Fort Worth, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Grapevine, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Lewisville, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Longview, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · McKinney, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Palestine, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Paris, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
  • Texas Oncology - Northeast Texas · Tyler, United StatesNot yet recruiting→Recruiting
Show 3 added (1 United States, 1 Australia, 1 Japan)
  • BRCR Global - Coral Springs · Coral Springs, United States
  • Albury Wodonga Private Hospital · West Albury, Australia
  • Aichi Cancer Center · Nagoya, Japan
Show 1 removed
  • US Oncology Investigational Products Center (IPC) · Irving, United States
across 2 updates, Sep 28, 2026 – Nov 18, 2026
Eligibility
1 inclusion criterion added, 1 removed; 3 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • RemovedParticipants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
  • AddedFor Phase 2 (except the Part B doublet cohort) and Phase 3: no prior systemic therapy for ES-SCLC. Participants who received 1 cycle of chemotherapy (without immunotherapy) for management of life-threatening ES-SCLC are eligible if all other criteria are met.
Exclusion criteria
  • ChangedBefore known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compressionNow Active central nervous system (CNS) lesions, including brainstem, meningeal, or spinal cord metastases/compression. Participants with adequately treated and stable brain metastases, or certain untreated asymptomatic brain metastases, may be eligible.
  • ChangedBefore Clinically significant risk of hemorrhage or fistulaNow Clinically significant risk of hemorrhage or fistula, including radiographic evidence of major blood vessel invasion/infiltration or tumor invasion of critical organs.
  • EditedhistoryHistory of another malignancy within 32 years, except for certain low-risk cancers.
  • AddedEvidence of non-infectious/drug-induced interstitial lung disease (ILD) or pneumonitis, or certain severe pulmonary conditions.
  • AddedUncontrolled significant comorbidities within 6 months before study treatment
Nov 18, 2026
Interventions
Added Drug: Tarlatamab·Drug: Atezolizumab; removed Biological: Atezolizumab. Arm changed Phase 2 Single arm→Phase 2 Part A - Chemo Combo Arm; Phase3 Control Arm→Phase 3 Control Arm. Arms added: Phase 2 Part B - Doublet Arm·Phase 2 Part B - Triplet Arm
Nov 18, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedPhase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessmentTime frame: Up to approximately 2 years after completion of study treatment of last study participant
Nov 18, 2026
Secondary outcomes
1 added, 2 description edited
What changed in the outcomes
  • AddedConfirmed ORR using RECIST v1.1 as assessed by investigatorTime frame: Up to approximately 2 years after completion of study treatment of last study participant
  • DescriptionDuration of Response (DOR) as assessed by Investigator based on RECIST v1.1: how it is measured was reworded
  • DescriptionPhase 3: Confirmed ORR using RECIST v1.1 as assessed by BICR: how it is measured was reworded
Nov 18, 2026
Title
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Nov 18, 2026
Show all 3 updates
  1. Nov 18, 2026
    3 sites added
    Show 3 added (1 United States, 1 Australia, 1 Japan)
    • BRCR Global - Coral Springs · Coral Springs, United States
    • Albury Wodonga Private Hospital · West Albury, Australia
    • Aichi Cancer Center · Nagoya, Japan
    Eligibility 1 inclusion criterion added, 1 removed; 3 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • RemovedParticipants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
    • AddedFor Phase 2 (except the Part B doublet cohort) and Phase 3: no prior systemic therapy for ES-SCLC. Participants who received 1 cycle of chemotherapy (without immunotherapy) for management of life-threatening ES-SCLC are eligible if all other criteria are met.
    Exclusion criteria
    • ChangedBefore known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compressionNow Active central nervous system (CNS) lesions, including brainstem, meningeal, or spinal cord metastases/compression. Participants with adequately treated and stable brain metastases, or certain untreated asymptomatic brain metastases, may be eligible.
    • ChangedBefore Clinically significant risk of hemorrhage or fistulaNow Clinically significant risk of hemorrhage or fistula, including radiographic evidence of major blood vessel invasion/infiltration or tumor invasion of critical organs.
    • EditedhistoryHistory of another malignancy within 32 years, except for certain low-risk cancers.
    • AddedEvidence of non-infectious/drug-induced interstitial lung disease (ILD) or pneumonitis, or certain severe pulmonary conditions.
    • AddedUncontrolled significant comorbidities within 6 months before study treatment
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedPhase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessmentTime frame: Up to approximately 2 years after completion of study treatment of last study participant
    Secondary outcomes 1 added, 2 description edited
    What changed in the outcomes
    • AddedConfirmed ORR using RECIST v1.1 as assessed by investigatorTime frame: Up to approximately 2 years after completion of study treatment of last study participant
    • DescriptionDuration of Response (DOR) as assessed by Investigator based on RECIST v1.1: how it is measured was reworded
    • DescriptionPhase 3: Confirmed ORR using RECIST v1.1 as assessed by BICR: how it is measured was reworded
    Interventions Added Drug: Tarlatamab·Drug: Atezolizumab; removed Biological: Atezolizumab. Arm changed Phase 2 Single arm→Phase 2 Part A - Chemo Combo Arm; Phase3 Control Arm→Phase 3 Control Arm. Arms added: Phase 2 Part B - Doublet Arm·Phase 2 Part B - Triplet Arm
    Title Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
    + 5 other changes: index terms, verification date, description, conditions and design details
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date
  3. Sep 28, 2026
    1 site removed. 23 sites changed recruiting status (23 now recruiting)
    Show 23 sites
    • University Hospitals Cleveland Medical Center · Cleveland, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Allen, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Arlington, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Bedford, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Dallas, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Denison, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Denton, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Flower Mound, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Fort Worth, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Grapevine, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Lewisville, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Longview, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · McKinney, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Palestine, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Paris, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - DFW · Plano, United StatesNot yet recruiting→Recruiting
    • Texas Oncology - Northeast Texas · Tyler, United StatesNot yet recruiting→Recruiting
    Show 1 removed
    • US Oncology Investigational Products Center (IPC) · Irving, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226999
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Dec 9, 2025
Primary completion
Jun 14, 2030 (estimated)
Completion
Mar 11, 2034 (estimated)
Last update
Nov 18, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion